Beyond Brexit: Smart Regulation for Investment and Patient Safety

Published: Posted on

The shape of the post-Brexit regulatory landscape has been the subject of much discussion in recent months. With the end of the transition period looming and the Government remaining scant on details, many academics and stakeholders have been exploring the possibilities. Reform, a Westminster think tank for public service reform, invited Dr Laura Downey, Dr Rachael Dickson, Professor Muireann Quigley, and Professor Jean McHale to share their thoughts on what is needed for a dynamic and responsive system of medicines and medical devices regulation post-Brexit.

Their contribution, emphasises the need to prioritise patient safety in any new systems. It draws on the findings of the Cumberlege Review which detailed harrowing experiences of patients’ concerns being ignored and overlooked. The Medicines and Medical Devices Bill that is currently progressing through Parliament does not, in its current form, provide enough assurances that patient safety is the priority of any new regulatory mechanisms.

 

Read the full analysis and recommendations to improve the role of MHRA by clicking on the image to the left. You can access the full Reformer Thoughts report and read the other contributions here.

Leave a Reply

Your email address will not be published.